Literature DB >> 33498872

The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma.

Alexander Ou1, Martina Ott2, Dexing Fang2, Amy B Heimberger2.   

Abstract

Glioblastoma remains one of the deadliest and treatment-refractory human malignancies in large part due to its diffusely infiltrative nature, molecular heterogeneity, and capacity for immune escape. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway contributes substantively to a wide variety of protumorigenic functions, including proliferation, anti-apoptosis, angiogenesis, stem cell maintenance, and immune suppression. We review the current state of knowledge regarding the biological role of JAK/STAT signaling in glioblastoma, therapeutic strategies, and future directions for the field.

Entities:  

Keywords:  JAK; STAT3; glioblastoma; immunotherapy; resistance

Year:  2021        PMID： 33498872      PMCID： PMC7865703          DOI： 10.3390/cancers13030437

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


  243 in total

Review 1.  Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.

Authors:  John J O'Shea; Massimo Gadina; Robert D Schreiber
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

2.  Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.

Authors:  Christine E Brown; Renate Starr; Brenda Aguilar; Andrew F Shami; Catalina Martinez; Massimo D'Apuzzo; Michael E Barish; Stephen J Forman; Michael C Jensen
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

3.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

4.  IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1.

Authors:  Ronghui Li; Gang Li; Lin Deng; Qinglin Liu; Jun Dai; Jie Shen; Jian Zhang
Journal:  Oncol Rep       Date:  2010-06       Impact factor: 3.906

5.  Alantolactone induces apoptosis in glioblastoma cells via GSH depletion, ROS generation, and mitochondrial dysfunction.

Authors:  Muhammad Khan; Fei Yi; Azhar Rasul; Ting Li; Nan Wang; Hongwen Gao; Rong Gao; Tonghui Ma
Journal:  IUBMB Life       Date:  2012-07-27       Impact factor: 3.885

6.  Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.

Authors:  Fable Zustovich; Lorenza Landi; Giuseppe Lombardi; Camillo Porta; Luca Galli; Andrea Fontana; Domenico Amoroso; Costanza Galli; Michele Andreuccetti; Alfredo Falcone; Vittorina Zagonel
Journal:  Anticancer Res       Date:  2013-08       Impact factor: 2.480

7.  STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.

Authors:  Balaram Thota; Arivazhagan Arimappamagan; Thennarasu Kandavel; Arun H Shastry; Paritosh Pandey; Bangalore Ashwathnarayanarao Chandramouli; Alangar Sathyaranjandas Hegde; Paturu Kondaiah; Vani Santosh
Journal:  J Neurosurg       Date:  2014-05-30       Impact factor: 5.115

8.  Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice.

Authors:  Leying Zhang; Darya Alizadeh; Michelle Van Handel; Marcin Kortylewski; Hua Yu; Behnam Badie
Journal:  Glia       Date:  2009-10       Impact factor: 7.452

9.  Coculture with astrocytes reduces the radiosensitivity of glioblastoma stem-like cells and identifies additional targets for radiosensitization.

Authors:  Barbara H Rath; Amy Wahba; Kevin Camphausen; Philip J Tofilon
Journal:  Cancer Med       Date:  2015-10-30       Impact factor: 4.452

10.  Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.

Authors:  Verena Leidgens; Judith Proske; Lisa Rauer; Sylvia Moeckel; Kathrin Renner; Ulrich Bogdahn; Markus J Riemenschneider; Martin Proescholdt; Arabel Vollmann-Zwerenz; Peter Hau; Corinna Seliger
Journal:  Oncotarget       Date:  2017-01-31
View more
  21 in total

Review 1.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

Review 2.  Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.

Authors:  Ruijia Liang; Cheng Wu; Shiming Liu; Wenyan Zhao
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 3.  New Approaches to Glioblastoma.

Authors:  Mustafa Khasraw; Yoko Fujita; Catalina Lee-Chang; Irina V Balyasnikova; Hinda Najem; Amy B Heimberger
Journal:  Annu Rev Med       Date:  2021-10-19       Impact factor: 16.048

Review 4.  Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways.

Authors:  Baokang Wu; Yizhou Zhang; Yang Yu; Chongli Zhong; Qi Lang; Zhiyun Liang; Chao Lv; Feng Xu; Yu Tian
Journal:  Front Cell Dev Biol       Date:  2021-12-16

5.  An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.

Authors:  Gang Xiao; Xuan Gao; Lifeng Li; Chao Liu; Zhiyuan Liu; Haiqin Peng; Xuefeng Xia; Xin Yi; Rongrong Zhou
Journal:  J Oncol       Date:  2021-12-18       Impact factor: 4.375

Review 6.  The mechanism of HMGB1 secretion and release.

Authors:  Ruochan Chen; Rui Kang; Daolin Tang
Journal:  Exp Mol Med       Date:  2022-02-25       Impact factor: 12.153

Review 7.  Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors.

Authors:  Federica Fabro; Martine L M Lamfers; Sieger Leenstra
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

Review 8.  Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.

Authors:  Julie Bolcaen; Shankari Nair; Cathryn H S Driver; Tebatso M G Boshomane; Thomas Ebenhan; Charlot Vandevoorde
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29

9.  Magnolol Induces the Extrinsic/Intrinsic Apoptosis Pathways and Inhibits STAT3 Signaling-Mediated Invasion of Glioblastoma Cells.

Authors:  Po-Fu Yueh; Yuan-Hao Lee; Chun-Yu Fu; Chun-Bin Tung; Fei-Ting Hsu; Keng-Li Lan
Journal:  Life (Basel)       Date:  2021-12-14

Review 10.  Proteomimetics of Natural Regulators of JAK-STAT Pathway: Novel Therapeutic Perspectives.

Authors:  Sara La Manna; Ilaria De Benedictis; Daniela Marasco
Journal:  Front Mol Biosci       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.